文献速递糖尿病

1型糖尿病患者超说明书使用SGLT2抑制剂与糖尿病酮症酸中毒发生率

Use of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis.
PubMed 文献 · Diabetes Care · 2019-10-10

该研究基于Sentinel系统2013年3月至2018年6月的数据,识别SGLT2抑制剂起始使用者,评估1型糖尿病患病率并计算DKA发生率。在475,527名起始使用者中,0.50%和0.92%分别符合窄和宽1型糖尿病标准,DKA发生率分别为7.3/100人年和4.5/100人年。超说明书使用SGLT2抑制剂的DKA观察值高于基于索格列净临床试验的预期值(SIR=1.83;95%CI 1.45-2.28)。

要点

  • 超说明书使用SGLT2抑制剂的1型糖尿病患者中DKA风险较高,尤其年轻女性。
  • 窄标准1型糖尿病患者DKA发生率为7.3/100人年,25-44岁女性高达19.7/100人年。
  • 真实世界DKA发生率超过索格列净临床试验预期(SIR=1.83;95%CI 1.45-2.28),但需谨慎解读。

核心结论

  • 超说明书使用SGLT2抑制剂的1型糖尿病患者中DKA风险显著,尤其在年轻女性患者中。

研究设计与样本

  • 基于Sentinel系统的回顾性队列研究,纳入2013年3月至2018年6月SGLT2抑制剂起始使用者,共475,527人。

主要发现

  • 窄和宽标准1型糖尿病患病率分别为0.50%和0.92%。
  • 窄和宽标准组DKA发生率分别为7.3/100人年和4.5/100人年。
  • 25-44岁女性窄标准患者DKA发生率最高,达19.7/100人年。
  • 观察到的DKA事件数高于基于索格列净临床试验的预期值(SIR=1.83;95%CI 1.45-2.28)。

关键数值与推荐

  • 窄标准1型糖尿病患者DKA发生率为7.3/100人年,宽标准为4.5/100人年。
  • 25-44岁女性窄标准患者DKA发生率为19.7/100人年。
  • 标准化发病比(SIR)为1.83(95%CI 1.45-2.28),比较真实世界与索格列净临床试验预期。

临床怎么用

  • 临床医生应警惕1型糖尿病患者超说明书使用SGLT2抑制剂时的DKA风险,尤其是年轻女性。
  • 处方SGLT2抑制剂给1型糖尿病患者时需加强DKA监测与患者教育。

局限性

  • 研究结果需谨慎解读,因研究方法、患者样本和研究药物存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To estimate real-world off-label use of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with type 1 diabetes, estimate rates of diabetic ketoacidosis (DKA), and compare them with DKA rates observed in sotagliflozin clinical trials. RESEARCH DESIGN AND METHODS: We identified initiators of SGLT2 inhibitors in the Sentinel System from March 2013 to June 2018, determined the prevalence of type 1 diabetes using a narrow and a broad definition, and measured rates of DKA using administrative claims data. Standardized incidence ratios (SIRs) were calculated using age- and sex-specific follow-up time in Sentinel and age- and sex-specific DKA rates from sotagliflozin trials 309, 310, and 312. RESULTS: Among 475,527 initiators of SGLT2 inhibitors, 0.50% and 0.92% met narrow and broad criteria for type 1 diabetes, respectively. Rates of DKA in the narrow and broad groups were 7.3/100 person-years and 4.5/100 person-years, respectively. Among patients who met narrow criteria for type 1 diabetes, rates of DKA were highest for patients aged 25-44 years, especially females aged 25-44 years (19.7/100 person-years). More DKA events were observed during off-label use of SGLT2 inhibitors in Sentinel than would be expected based on sotagliflozin clinical trials (SIR = 1.83; 95% CI 1.45-2.28). CONCLUSIONS: Real-world off-label use of SGLT2 inhibitors among patients with type 1 diabetes accounted for a small proportion of overall SGLT2 inhibitor use. However, the risk for DKA during off-label use was notable, especially among young, female patients. Although real-word rates of DKA exceeded the expectation based on clinical trials, results should be interpreted with caution due to differences in study methods, patient samples, and study drugs.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Hampp C, Swain RS, Horgan C, et al. Use of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis. Diabetes Care. 2019. PMID: 31601640. doi:10.2337/dc19-1481

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。